Last reviewed · How we verify
NCT04919863
Safety, Tolerability and Pharmacokinetics of NTP42:KVA4
Phase 1 trial testing NTP42:KVA4 in Healthy in 79 participants. Completed in 20 January 2022.
20 January 2022
Quick facts
| Lead sponsor | ATXA Therapeutics Limited |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 79 |
| Start date | 24 May 2021 |
| Primary completion | 20 January 2022 |
| Estimated completion | 20 January 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- NTP42:KVA4
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
ATXA Therapeutics Limited — full company profile →
Who can join
Adults 18 to 55, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics of NTP42:KVA4 following oral administration in a randomized, double-blind, placebo-controlled trial. The trial will involve of 2 phases, a single ascending dose (SAD) phase and a multiple ascending dose (MAD) phase. The SAD phase will incorporate a food effect arm.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The thromboxane receptor antagonist <i>NTP42</i> promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload.
Mulvaney EP, Renzo F, Adão R, Dupre E, et al · · 2022 · cited 6× · PMID 36588576 · DOI 10.3389/fcvm.2022.1063967 -
Evaluation of <i>NTP42</i>, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial.
Reid HM, Maginn M, Perkins CM, Mulvaney EP, et al · · 2023 · cited 2× · PMID 38178863 · DOI 10.3389/fphar.2023.1296188
Verify or expand the search:
- PubMed search for NCT04919863
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other ATXA Therapeutics Limited trials
Trials by the same sponsor.
- NCT06092788 — Safety, Pharmacokinetics (PK) and Relative Bioavailability of NTP42:KVA4 as a Solid Oral Dose · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04919863 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ATXA Therapeutics Limited
- Last refreshed: 24 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04919863.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing